General Information
BounceWatch is an independent company data service, not affiliated with Adcendo. To contact Adcendo, visit adcendo.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Adcendo compare?
A PDF of Adcendo and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Adcendo soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Adcendo on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
Denmark Market
Biotechnology
About Adcendo
Business keywords: Biotech, Antibody-drug conjugates, Cancer treatment, Drug development, Copenhagen, Denmark, Finsen Laboratory, Rigshospitalet, University of Copenhagen, Spin-out company, Anti-cancer drugs, Novel targets, Overexpressed targets, Unmet medical need, Research and development
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| B | $135.00M | 13 | 25 Nov 2024 | |
| Series A | €16.00M | 7 | 29 May 2024 | |
| Series A | €31.00M | 3 | 04 Apr 2023 | |
| Series A | €51.00M | - |
|
29 Apr 2021 |
| Debt Financing | kr10.00M | - |
|
29 Aug 2019 |
| Grant | Undisclosed | - |
|
01 Jan 2018 |
Latest News
View AllAdcendo Alternatives & Competitors
View All AlternativesImproving patient outcomes through innovations in biological therapeutics
First-in-class ADCs tailored to attack advanced cancer
FAQ About Adcendo
Source: BounceWatch company record for Adcendo, https://www.bouncewatch.com/company/adcendo, updated 30 December 2024. When citing, please name BounceWatch and link this page.